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Fibronectin leucine-rich repeat transmembrane pro-
teins (FLRTs) are cell-adhesion molecules with
emerging functions in cortical development and syn-
apse formation. Their extracellular regions interact
with latrophilins (LPHNs) to mediate synapse devel-
opment, and with Uncoordinated-5 (UNC5)/netrin
receptors to control the migration of neurons in
the developing cortex. Here, we present the crystal
structures of FLRT3 in isolation and in complex with
LPHN3. The LPHN3/FLRT3 structure reveals that
LPHN3 binds to FLRT3 at a site distinct from UNC5.
Structure-based mutations specifically disrupt
LPHN3/FLRT3 binding, but do not disturb their inter-
actions with other proteins or their cell-membrane
localization. Thus, they can be used as molecular
tools to dissect the functions of FLRTs and LPHNs
in vivo. Our results suggest that UNC5 and LPHN3
can simultaneously bind to FLRT3, forming a trimeric
complex, and that FLRT3 may form transsynaptic
complexes with both LPHN3 and UNC5. These find-
ings provide molecular insights for understanding
the role of cell-adhesionproteins in synapse function.
INTRODUCTION
During neural development, immature neurons migrate from
their birthplaces in the embryo to their final positions, and com-
plete synaptic circuits. Outgrowth of axons and dendrites from
neurons, guidance of themotile growth cone through the embryo
toward postsynaptic partners, and the generation of synapses
between these axons and their postsynaptic partners are essen-
tial landmarks of neural development that are each mediated by
a complex interaction network of cell-surface proteins on the
nerve cells. Distinct properties of each neuron and its synaptic
connections are also a function of the cell-adhesion molecules
expressed on its surface and the interactions in which thesemol-
ecules are involved. An imperfection in any of these steps may
lead to malformations or inappropriate connectivity of the brain,
and is believed to be involved in many neurodevelopmental dis-1678 Structure 23, 1678–1691, September 1, 2015 ª2015 Elsevier Ltorders such as attention deficit/hyperactivity disorder (ADHD),
autism, and brain cancers (Asherson and Gurling, 2012; Sudhof,
2008). Although the role of binary protein-protein interactions is
commonly studied and understood, it is likely that the presence
or absence of ternary, quaternary, and even higher-order pro-
tein-protein interactions are determinants for the buildup of a
network as complex as exists in the brain. However, the mole-
cules and the underlyingmechanisms of such complex phenom-
ena are unclear.
Fibronectin leucine-rich repeat transmembrane (FLRTs) pro-
teins are cell-surface molecules that contribute to early embry-
onic, vascular, and neural development (Egea et al., 2008;
Leyva-Diaz et al., 2014; Maretto et al., 2008; Muller et al., 2011;
O’Sullivan et al., 2012; Yamagishi et al., 2011). FLRTs are type I
membrane proteins with extracellular regions consisting of a
leucine-rich repeat (LRR) domain with ten LRR repeats, and a
fibronectin type 3 domain followed by a juxtamembrane linker
(Lacy et al., 1999) (Figure 1A). FLRTs are expressed in many tis-
sues, including brain (Bottcher et al., 2004; Lacy et al., 1999),
and different FLRT isoforms (FLRT1–3) have different cell type-
specific expression patterns in the hippocampus and cortex (Al-
len Institute for Brain Science, 2009). FLRTs interact with the
axonal guidance receptors Uncoordinated-5B (UNC5B) and
UNC5D proteins (Yamagishi et al., 2011). Their ectodomains
are suggested to shed from neurons to act as repulsive cues in
axon guidance and neuron migration (Sollner and Wright, 2009;
Yamagishi et al., 2011). FLRTs have also been identified as
high-affinity endogenous ligands for latrophilins (LPHNs) and
were suggested to play a role in glutamatergic synapse develop-
ment (O’Sullivan et al., 2012, 2014). Moreover, FLRT proteins
interact with each other and may promote homotypic cell adhe-
sion, and are additionally implicated in fibroblast growth factor
signaling during development (Karaulanov et al., 2006; Bottcher
et al., 2004; Maretto et al., 2008). The N-terminal LRR domain
of FLRTs is reported to be involved in all reported interactions
of FLRTs (Karaulanov et al., 2006, 2009). The involvement of
LRR domains of FLRTs in numerous heterophilic interactions
suggests a central role for FLRTs in neural development, and rai-
ses the necessity to identify the specific binding sites for each of
LRR domain interactions (such as latrophilin, UNC5, and homo-
philic FLRT-binding sites on FLRT) in order to unambiguously
dissect the role of each interaction for FLRT function.
Latrophilins (LPHN1–3) are cell-surface molecules that belong
to the adhesion-type G-protein-coupled receptor (GPCR) familyd All rights reserved
(Krasnoperov et al., 1996; Lelianova et al., 1997). LPHN1 was
identified as the calcium-independent receptor for a-latrotoxin,
a black widow spider toxin that triggers massive neurotrans-
mitter release from neurons and neuroendocrine cells (Deak
et al., 2009; Krasnoperov et al., 1997; Lelianova et al., 1997; Sud-
hof, 2001; Sugita et al., 1999). Mutations of LPHNs have been
linked to ADHD as well as numerous cancers (Arcos-Burgos
et al., 2010; Kan et al., 2010; O’Hayre et al., 2013). LPHNs are
highly expressed in the brain (Sugita et al., 1998), and were
shown to function as heterophilic cell-adhesion molecules in
processes such as synapse formation or maintenance. They
are the only adhesion-type GPCRs besides flamingo-like CELSR
proteins that are conserved between vertebrates and inverte-
brates. In Caenorhabditis elegans, LPHN1 homolog Lat-1 is
required for the alignment of cell division planes to the ante-
rior-posterior axis during development (Langenhan et al.,
2009). In Drosophila, latrophilin/dCIRL sensitizes the chordoto-
nal neurons to modulate the perception of mechanical signals
(Scholz et al., 2015). In vertebrates, LPHN3 and FLRT3 were re-
ported to interact in trans through their ectodomains to mediate
cell adhesion, an interaction that promotes the development of
glutamatergic synapses (O’Sullivan et al., 2012). LPHNs have
large extracellular sequences that contain an N-terminal lectin
domain, a central olfactomedin (Olf) domain, a serine/threo-
nine-rich region, a hormone-binding domain, and a C-terminal
conserved GPCR autoproteolysis-inducing (GAIN) domain that
mediates autoproteolysis (Arac et al., 2012; Sugita et al., 1998;
Krasnoperov et al., 1996; Lelianova et al., 1997) (Figure 1A).
The LPHNOlf domain is required for its synapse-promoting func-
tion and also for FLRT binding (O’Sullivan et al., 2014). Similarly
to FLRTs, LPHNs are also involved in numerous interactions. In
addition to FLRTs, LPHNs interact with the members of the ten-
eurin/ODZ family proteins (Boucard et al., 2014; Levine et al.,
1994; Silva et al., 2011) andwith neurexins (Boucard et al., 2012).
UNC5A–D receptors are type I membrane proteins with extra-
cellular regions containing two immunoglobulin domains and
two thrombospondin domains (Figure 1A). UNC5 receptors
bind to secreted netrin ligands that act as repulsive cues during
the development of the neural system to regulate neuronal
migration (Sun et al., 2011). However, the migration of UNC5D-
expressing neurons in the developing cortex, where netrin is
not expressed, is regulated by FLRTs (Yamagishi et al., 2011).
The crystal structure of UNC5D in complex with the LRR domain
of FLRT2 has revealed the binding interface, and it was sug-
gested that during cortical development the repulsive FLRT-
UNC5 interaction mediates radial (upward) migration of neurons,
whereas the adhesive homophilic FLRT-FLRT interaction is
important for the tangential (sideways) migration of neurons
(Seiradake et al., 2014). However, the effect of other interactions
on the function of these proteins, for example a possible simul-
taneous interaction of FLRT with LPHN3, was not clarified. In
particular, the crystal structure suggests that FLRT dimers may
exist in cis, casting doubt on the notion that hemophilic cell
adhesion can be mediated by FLRTs.
FLRTs and LPHNs work together with other proteins such as
UNC5s to support the formation of proper neuronal connections.
Although the FLRT/UNC5 crystal structure is available, the
LPHN/FLRT structure and well-characterized mutations that
abolish a single interaction of each protein while maintainingStructure 23, 1678–16the other interactions are not known. The presence of multiple
binding partners and their compatibilities with each other, the
formation of cis, trans, or both interactions between proteins,
and the presynaptic or postsynaptic localization of each protein
are additional complications that need to be addressed to deci-
pher the mechanism of action of these proteins in neural devel-
opment. We determined the three-dimensional structures of
FLRT3 in isolation and in a complex with LPHN3 by X-ray crystal-
lography. The structure of the complex reveals a large LPHN3-
binding interface on the concave surface of FLRT3, which was
previously reported as the dimerization surface. We designed
multiple mutations on the LPHN3-binding surface of FLRT3
and the FLRT3-binding surface of LPHN3 to specifically disrupt
the interaction between them. We confirmed the wild-type (WT)-
like folding and trafficking of the mutant FLRT3s and mutant
LPHN3s. The mutations that disrupt the LPHN3/FLRT3 interac-
tion without interfering with folding or trafficking confirm the
binding interface revealed by the LPHN3/FLRT3 complex struc-
ture. These mutants can be used as molecular tools to dissect
the LPHN3/FLRT3 interaction in vivo. We also studied the previ-
ously reported FLRT3 mutants called ‘‘FLRT3 dimerization
mutant’’ and ‘‘UNC5-binding mutant’’ (Seiradake et al., 2014),
and found that the FLRT3 dimerization mutant that was reported
to abolish tangential (sideways) migration of neurons during cor-
tex development is indeed defective in LPHN3 binding more
severely than in dimerization. Our flow cytometry experiments
showed that FLRT3, LPHN3, and UNC5 form a trimeric complex.
FLRT3 binds the other two proteins simultaneously and bridges
them, although LPHN3 and UNC5 do not directly interact with
each other. Finally, we demonstrate that both the LPHN/FLRT
pair and the FLRT/UNC5 pair can interact in trans and cause
cell aggregation, suggesting that these protein-protein com-
plexes are transsynaptic complexes.
RESULTS
Structure of the LPHN3/FLRT3 Complex
To determine the structure of the LPHN3/FLRT3 complex, the
extracellular LRR domain of human FLRT3 (residues K29–
D357, corresponding to the N-terminal cap, LRR repeats, and
C-terminal cap) and the Olf domain of LPHN3 (residues V132–
G392) were produced in insect cells using the baculovirus
expression system (residue numbering includes signal peptide
even when it is absent). After purification of individual proteins
the complexwas formed, and purified by size-exclusion chroma-
tography. The formation of the complex is independent of cal-
cium as observed by native gel analysis (data not shown). Crys-
tals of the complex were obtained in space group P43 with four
LPHN3/FLRT3 complexes in the asymmetric unit, and diffracted
to dmin = 3.6 A˚ (Table 1). The complex structure was obtained by
molecular replacement using the available mouse FLRT3 struc-
ture (PDB: 4V2E) and the mycolin Olf structure (PDB: 4WXQ,
kindly provided by Raquel Lieberman before its release), and
was further refined by the recently released human LPHN3 Olf/
lectin structure (PDB: 5AFB) (Donegan et al., 2015; Jackson
et al., 2015; Seiradake et al., 2014).
We also determined the crystal structure of the isolated human
FLRT3 at a unit cell different from the previously published
mouse FLRT3 (Figure S1). Crystals of FLRT3 were obtained in91, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1679
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Figure 1. Crystal Structure of the LPHN3/FLRT3 Complex
(A) Schematic diagram of vertebrate LPHN3, FLRT3, and UNC5D showing their domains.
(B) Ribbon diagram of the LPHN3/FLRT3 heterodimer.
(C) Surface representation of the LPHN3/FLRT3 heterodimer.
(legend continued on next page)
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Table 1. Data Collection and Refinement Statistics
FLRT3 LPHN3/FLRT3 Complex
Data Collection
Wavelength 0.96638 1.00883
Space group P21 P43
Cell dimensions
a, b, c (A˚) 76.140, 106.581,
84.152
102.268, 102.268,
419.23
a, b, g () 90, 90.31, 90 90, 90, 90
Resolution (A˚) 50–2.601 (2.64–2.60)a 73.2–3.60 (3.66–3.60)a
Rsym 0.144 (0.640) 0.262 (0.634)
CC1/2 0.763
(high-resolution shell)
0.671
(high-resolution shell)
Completeness (%) 95.7 (73.1) 98.3 (79.3)
Redundancy 8.8 (1.6) 8.9 (1.5)
Refinement
Resolution (A˚) 45–2.60
(2.67–2.60)
73.20–3.60
(3.71–3.60)
No. of reflections 39,414 (1,492) 45,263 (1,507)
Rwork 0.2344 (0.2973) 0.2004 (0.2508)
Rfree 0.2956 (0.4364) 0.2621 (0.3460)
No. of atoms
Protein 10,300 18,360
Ligand/ion 56/0 56/4
B factors
Protein 48.138 117.938
Ligand/ion 40.311 118.261
Root-mean-square deviations
Bond lengths (A˚) 0.0123 0.006
Bond angles () 1.330 0.983
Ramachandran statistics
Favored (%) 90.28 93.5
Outliers (%) 0 0
aValues in parentheses are for highest-resolution shell. CC1/2, half dataset
correlation coefficient. NA, not applicable.space group P21 with four molecules in the asymmetric unit and
diffracted to dmin = 2.6 A˚. The structure was solved by molecular
replacement using the available mouse FLRT3 structure as a
model (PDB: 4V2E) (Table 1). As described previously, FLRT3
has a horseshoe shape with dimensions 83 3 32 3 40 A˚, and
contains ten LRR repeats (Seiradake et al., 2014).
The crystal structure of the LPHN3/FLRT3 complex comprises
a heterodimer in which the five-bladed b-propeller LPHN3 Olf
domain (dimensions 52 3 43 3 43 A˚) docks into the groove
on the concave surface of the horseshoe-shaped FLRT3 LRR(D) The structure of the LPHN3/FLRT3 complex is shown in surface representat
(magenta) to least conserved (cyan) (using the ConSurf server; Landau et al., 2005
each other, are indicated by yellow circles.
(E) Positive (blue) and negative (red) electrostatic isosurfaces calculated at conto
structures.
The structures in (C) to (E) are shown in an orientation similar to that in (B).
See also Figure S1.
Structure 23, 1678–16domain, creating a large buried surface area of 1,550 A˚2 (Figures
1B and 1C). There were no other significant heterotypic interac-
tions in the crystal lattice (Figures S1D and S1E; see Figures
S1A–S1C for a discussion of homotypic interactions). Apart
from side-chain rotamer changes, no major conformational
changes are observed when the complex structure is compared
with the individual structures of FLRT3 or LPHN3. N-Linked
glycosylation is observed at one (residue N226) glycosylation
site on FLRT3, and three disulfide bonds (C31-C37, C35-C44,
C309-C334) are observed in the FLRT3 LRR domain. A single di-
sulfide bond (C135-C317) and no glycosylation is observed in the
LPHN3Olf domain. The relative orientation of LPHN3 to FLRT3 is
consistent with the previous prediction based on mutagenesis
(Jackson et al., 2015). However, numerous differences exist in
the fine details of the molecular interactions.
The LPHN3-binding region on FLRT3 is located at the top of
the inside concave surface of the LRR domain close to the N-ter-
minal cap (Figures 1B and 1C). This region is away from the
UNC5-binding region on FLRT3 (Seiradake et al., 2014). How-
ever, it is at the same side as the previously reported dimerization
surface (see discussion below for the compatibility of these inter-
actions with each other). The FLRT3-binding region on LPHN3 is
located at the top/side surface of the Olf domain and is mediated
by the conserved loops primarily in the second and third blades.
The blades of the Olf domain are asymmetrical, and the fifth
blade from where the N and C termini emerge is larger than the
other blades, spanning as much space as almost two blades.
This type of b-propeller structure was also recently observed in
the structure of the Olf domain of gliomedin (Han and Kursula,
2015).
There is electron density at the same position as of the Ca2+
ion in the isolated Olf-lectin structure (PDB: 5AFB). The FLRT3-
binding site is opposite to the N and C termini of the Olf domain
that connect to the lectin and STP/HormR/GAIN/TM domains,
respectively. The alternatively spliced sequence (residues
K127–K131) between the lectin and Olf domains of LPHN3 is
located immediately N-terminal of the Olf domain, distant from
the FLRT3-binding region, explaining why its presence does
not affect FLRT3 binding to LPHN3 (Boucard et al., 2014). The
LPHN3/FLRT3 complex structure also explains why FLRT bind-
ing is mediated by only theOlf domain (O’Sullivan et al., 2014), as
opposed to teneurin binding that is mediated by both the lectin
and Olf domains and the splice insert between them (Boucard
et al., 2014). As both the N and C termini of the Olf domain reside
next to each other, it is not possible to conclude from the LPHN/
FLRT structure whether the LPHN3/FLRT3 interaction is in trans
or cis.
The sequence identities between FLRT LRR domains and the
sequence identity between the LPHN Olf domains are high
(Tables S1 and S2). Although invertebrate LPHN homologs
lack an Olf domain, it is the most conserved extracellular domainion on which the conservation of residues are mapped from most conserved
). The LPHN-binding site and the FLRT binding site, where they come closest to
urs ±2 kT/e using PDB2PQR and APBS for LPHN3, FLRT3, and the complex
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of LPHNs in vertebrates, suggesting an essential function. Simi-
larly, no direct FLRT homolog is readily identifiable in inverte-
brates. To visualize conserved and variable regions of FLRT
LRR domains and LPHNOlf domains, we mapped the conserva-
tion of residues on the LPHN3/FLRT3 complex structure, and
colored residues from most conserved to least conserved. The
binding surfaces of FLRTs and LPHNs to each other correspond
to one of the most conserved regions (yellow ovals in Figure 1D).
Visualization of the electrostatic surface potential on the com-
plex structure shows that the inside concave surface of the
LRR domain is positively and negatively charged on separate
sides, suggesting that charge-mediated interactions are likely
to be mediated by this concave surface (Figure 1E). The binding
interface of FLRT and LPHN is not highly charged.
Mutations at the Binding Surface Disrupt the Interaction
of FLRT3 and LPHN3
The high affinity of the LPHN3/FLRT3 complex (Kd = 220–260 nM
as determined by bio-layer interferometry [BLITZ], Figure S2;
O’Sullivan et al., 2012) is achieved by a combination of interac-
tions, comprising hydrogen bonds, salt bridges, hydrophobic in-
teractions, and long-range electrostatic interactions (Figure 2A).
The docking of the complementary surfaces of the round-
shaped Olf domain into the concave surface of the LRR domain
creates a large interface. Our observed binding affinity and the
observed interface area of the LPHN3/FLRT3 complex are in
line with a study that demonstrates correlation of the binding af-
finity with interface area (Chen et al., 2013). Numerous polar res-
idues are at the binding interface (Figure 2A).
Mapping the residues that are mutated in some ADHD (A247S
in human LPHN3; Domene et al., 2011) and cancer cases
(R196C, A278P, and A278T in human LPHN2; Kan et al., 2010;
O’Hayre et al., 2013) on the LPHN3/FLRT3 structure reveals
that A247S and A278P/T mutations map close to the binding
interface, and thus may cause a direct defect in binding to
FLRT3 (Figures 2B and 2C). The R196Cmutation is at the distant
edge of the binding interface. Interestingly, the A278P/T muta-
tion that is very close to the binding interface is mutated to two
different residues in cancers and is reported by two different
studies (Kan et al., 2010; O’Hayre et al., 2013).
To specifically abolish a single interaction without interfering
with other interactions or cell-surface localization of FLRT3 and
LPHN3, and to confirm the validity of the binding interface that
is observed in the LPHN/FLRT complex structure, we designed
surface mutations on full-length FLRT3 (FL-FLRT3) and full-
length LPHN3 (FL-LPHN3) that change only a few atoms on
the protein surface rather than introduce large post-translational
modifications (Figure 2B). We designed mutations on LPHN3 to
abolish binding to FLRT3, and mutations on FLRT3 to abolish
binding to LPHN3. In designing all of these mutants, we tried
to avoid any interference with the folding of the proteins. We
also studied the previously published FLRT3 dimerizationmutant
(‘‘FF’’: R181N, D183T) and the FLRT3 mutant that abolishes
UNC5 binding (‘‘UF’’: H165N). (See Table 2 for a full list of all mu-
tations on the complex structure; see Figure 2C for a schematic
representation of select importantmutations; see Figures 2D and
2E for conservation of the residues at the binding sites.)
We first examined the expression levels and surface transport
of all FL-FLRT3 and FL-LPHN3 mutants to eliminate misfolded1682 Structure 23, 1678–1691, September 1, 2015 ª2015 Elsevier Ltmutants that are likely to be poorly expressed and unlikely to
reach the cell surface. The FL-FLRT3 and FL-LPHN3 had extra-
cellular N-terminal Myc and Flag tags, respectively, to allow for
detection of expression levels and cell-surface localization of
WT and mutant proteins. We expressed WT and mutant full-
length FLRT3 and LPHN3 in transfected HEK293 cells. Cells
were stained without detergent permeabilization (to label only
the cell-surface localized protein), with an antibody suitable to
react with the extracellular tag on the proteins, and the amount
of surface-exposed FL-FLRT3 or FL-LPHN3 was detected by in-
direct immunofluorescence using flow cytometry (Figures 3, 4,
and S3–S5; Table S3).
We next measured soluble FLRT3 LRR binding to all FL-
LPHN3 mutants, using surface binding of recombinant FLRT3
LRR domain to HEK293 cells transfected with full-length WT or
mutant LPHN3s using flow cytometry (Figures 3 and S4; see Fig-
ure S3 and Table S3 for details). To ensure the mutations
completely abolish binding, low and high concentrations of WT
recombinant FLRT3 LRR were used in binding experiments.
Specifically, by staining with purified FLRT3 LRR at concentra-
tions as low as 10 nM, only high-affinity interactions can be
detected. By staining at concentrations as high as 10 mM,
lower-affinity interactions can be detected. In addition, by stain-
ing with tetramerized FLRT3 LRR, the avidity effect increases the
effective concentration by more than 100-fold (Wooldridge et al.,
2009) (His-FLRT3 was tetramerized by mixing with biotin-tris-ni-
trilotriacetic acid [BTtrisNTA] and neutravidin, a protein that
binds to biotin and tetramerizes it). Thus, by observing no bind-
ing of 100 nM tetramerized FLRT3 LRR to mutant FL-LPHN con-
structs, we concluded that the affinity for WT FLRT3 LRR for
these LPHN3 mutants was very low (i.e. Kd > 10 mM).
These experiments showed that FL-LPHN3-M21 (Y249A,
D251A, T252A, R308A) and FL-LPHN3-M28 (Y249A, D251A,
T252A, E279A, R308A) mutants were defective in FLRT LRR
binding and had no surface localization problems (Figures 3A
and 3B). Similar experiments were performed to test WT recom-
binant LPHN3 Olf domain binding to HEK293 cells transfected
with full-length WT or mutant FLRT3s (biotinylated LPHN3 Olf
was tetramerized by mixing with neutravidin). FL-FLRT3-M02
(Y43A, Y64A) and FL-FLRT3-M06 (D38A, Y43A, N45A, R47A)
mutants were defective in LPHN3 Olf binding and had no
surface localization problems (Figures 4A and 4B, Figure S5;
see Figure S3 and Table S3 for details). To further confirm the
proper folding and stability of the mutants, we also performed
differential scanning fluorimetry experiments with select mutants
that measure the stability of proteins by monitoring the melting
temperature (Figure 4C). Mutant FLRT3 LRR and mutant
LPHN3 Olf proteins expressed and purified in baculovirus
expression system were used for these experiments. Together,
thesemutants that are transported to the cell surface and exhibit
either a defect in FLRT3 binding or LPHN3 binding, or no
apparent defect provide us with a toolkit to explore the function
of LPHN3 and FLRT3 in the neuronal activities of these cell-
adhesion proteins.
We also studied the previously reported FLRT3mutants called
‘‘FLRT3-FF dimerization mutant’’ and ‘‘FLRT3-UF UNC5-binding
mutant’’ (see Figure 2C for a schematic illustration of their
location on the complex structure) (Seiradake et al., 2014).
These mutations, however, were generated by introducing larged All rights reserved
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Figure 2. Binding Interface between FLRT3 and LPHN3
(A) Ribbon diagram showing the entire interface between FLRT3 and LPHN3. Polar interactions are shown by dashed lines. Residues at the binding interface are
shown as sticks.
(B) Close-up view of the binding interface between FLRT3 and LPHN3 (box in A). Labeled residues correspond to the residues that were mutated in the selected
M02, M06, M21, and M28 mutants. Red spheres show the locations of the ADHD and cancer mutations on LPHNs.
(C) Schematic drawing of locations of mutations studied in this article (labeled in black) and three disease mutations (labeled in red). Dashed black spheres
indicate the N-linked glycosylation moieties introduced as a result of mutagenesis. Carbohydrates on FLRT3-FF mutant clash with LPHN3.
(D) Sequence alignment of the FLRT-binding site on different Olf domain sequences. The key residues involved in binding to FLRT are highlighted in cyan. Disease
mutations are highlighted in red. The residues essential for binding to FLRTs are conserved only in LPHNs. Conservation of each residue is labeled. Value 9
corresponds to highest conservation.
(E) Sequence alignment of the LPHN-binding site on FLRT sequences. The conserved cysteines are highlighted in black. The key residues involved in binding to
LPHN are highlighted in cyan. Disulfide bonds are indicated by black lines.
See also Figure S2.
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Table 2. Summary of Mutations and Their Characteristics
hLPHN3
Mutant
Name Mutations
Cell-Surface
Localization
FLRT3 LRR
Binding
WT +++ +++
M19 Y249A +++ +++
M20 Y249A, D251A, T252A +++ +
M21a Y249A, D251A, T252A, R308A +++ 
M22 Y177A, Y249A, R205A ++ +
M23 N248A, Y249A + 
M24 N248A, Y249A, E279A + 
M27 D251A, T252A ++ +
M28a Y249A, D251A, T252A,
E279A, R308A
+++ 
hFLRT3
Mutant
Name Mutations
Cell-Surface
Localization
LPHN3 Olf
Binding Dimerization
WT +++ +++ +++
M01 Y89A, Y91A ++ 
M02 Y43A, Y64A +++  +++
M03 Y43A, Y64A,Y89A,
Y91A
+ 
M04 Y64A, Q66A, N67A  
M05 Y43A, N45A, R47A +++ 
M06 Y43A, N45A, R47A,
D38A
+++ 
M08 R117A, E113A +++ ++ +++
M11 R181A, D183A +++
M26 Q66A, N67A + 
M35 Y43A, Y89A, Y91A + 
FLRT-UF H165N +++ +++ +++
FLRT-FF R181N, D183T +++  +
a100 nM tetramerized FLRT3 LRR binding shown for M21 and M28 mu-
tants (Figure 3). 10 mMmonomeric FLRT3 LRR binding shown for all other
FL-LPHN3 mutants (Figure S4).N-linked carbohydrate modifications into the protein surface to
disrupt interactions. In vivo studies performed with these mu-
tants had reported that FLRT dimerization is involved in tangen-
tial (sideways) migration of neurons during cortex development,
whereas repulsive FLRT-UNC5 interaction is involved in radial
(upward) migration of neurons. Our further analysis of these mu-
tants showed that FLRT3-FF decreases dimerization although it
does not abolish it (see below, Figures 5A and 5B). Importantly it
completely abolishes the binding of LPHN3Olf to FL-FLRT3 (Fig-
ures 4A and 4B), suggesting that the in vivo effect of the FLRT3-
FF mutant on tangential migration of neurons is likely due to the
lack of LPHN3 binding to FLRT3. The UNC5-binding mutant
FLRT3-UF, on the other hand, had no detectable effect on
LPHN3 binding (Figures 4A and 4B).
Effect of Mutations on FLRT3 Dimerization
Next, we tested the effect of the FLRT3 mutations on FLRT3
dimerization. It was previously reported that gel filtration chro-
matography can detect the concentration-dependent dimeriza-1684 Structure 23, 1678–1691, September 1, 2015 ª2015 Elsevier Lttion of FLRT3 LRR (Seiradake et al., 2014). As expected, the
size-exclusion chromatogram of purified FLRT3 LRR showed
that the protein concentration affects the elution volume, indi-
cating that at high protein concentrations FLRT3 LRR forms a
dimer, whereas at low protein concentrations FLRT3 LRR is a
monomer (Figure 5A, notice the correlation of the elution volume
with the absorbance units [mAu] reflective of protein concentra-
tion; see Figure S6 for elution profiles of gel filtration standards,
dimeric FLRT3 LRR, LPHN3 Olf, and the LPHN3/FLRT3 com-
plex). At intermediate concentrations, the eluted peak was in be-
tween the dimer and monomer elution volumes. We speculate
that the monomer/dimer has a fast exchange rate giving rise to
a single intermediate peak rather than a mixture of monomer/
dimer peaks. When dimer was diluted and re-run on the gel filtra-
tion column, a monomer peak was observed. Similarly, when the
monomer peak was concentrated and re-run, a dimer peak was
observed, showing that the dimer-monomer formation is revers-
ible. Based on the measured protein concentrations, a low affin-
ity in the submicromolar range is predicted for the FLRT3 LRR
dimer in vitro. However, the affective affinity of two FL-FLRT3
monomers involved in a possible cis interaction on the cell sur-
face is likely higher.
We used gel filtration chromatography to monitor the effect of
the studied FLRT mutations on the ability of FLRT LRR to
dimerize. The reported FLRT dimerization mutant (FLRT3-FF)
decreased dimerization but did not completely abolish it (Fig-
ure 5B). When we mutated the same residues to alanine without
introducing a glycosylation site (M11, R181A, D183A instead
of R181N, D183T), FLRT3 LRR dimerization was not affected
(Figure 5C), suggesting that the large glycosylation moiety intro-
duced to the surface of the concave side of FLRT3 LRR in the
FLRT-FF mutant is blocking FLRT3 dimerization due to steric
hindrance rather than breaking specific molecular interactions.
This result demonstrates that the introduction of carbohydrates
to a site can block protein interactions dramatically. In addition,
we tested our FLRT3 mutant that does not bind to LPHN3
(M02) for dimerization, and showed that its dimerization ability
is not affected (Figure 5D); thus it can be used as a specific
LPHN3-binding mutant in further experiments. The FLRT-UF
mutant, on the other hand, showed WT-like dimerization ability
(Figure 5E).
FLRT3, LPHN3, and UNC5 Form a Trimeric Complex
FLRT proteins are involved in heterodimeric interactions with
LPHNs and with UNC5s, and in homodimeric interactions with
themselves. However, whether all of these interactions are
compatible is unclear. We next investigated whether FLRT3/
UNC5 interaction is compatible with LPHN3/FLRT3 interaction
or, in other words, whether FLRT3, LPHN3, and UNC5 can
form a trimeric complex. The availability of the LPHN3/FLRT3
complex structure and the previously reported FLRT3/UNC5
complex structure (Seiradake et al., 2014) enabled us to
compare structures and predict, then test, the compatibility
of the possible interactions of FLRT3 with each other. Intrigu-
ingly, superimposition of the LPHN3/FLRT3 structure with the
FLRT3/UNC5 structure suggests that UNC5 and LPHN3 bind
to distinct surfaces on FLRT3 and that there are no clashes be-
tween UNC5 and LPHN3, suggesting that LPHN3 and UNC5
can bind to FLRT3 simultaneously (Figure 6A).d All rights reserved
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Figure 3. Mutations on LPHN3 Abolish FLRT3 Binding But Do Not Interfere with Proper Cell-Surface Localization
(A) Wild-type (WT) and mutant full-length LPHN3 proteins were tested for surface expression in HEK293 cells as well as their ability to bind soluble FLRT3 LRR
domain using flow cytometry. Non-permeabilized HEK293 cells expressing N-terminally FLAG-tagged FL-LPHN3 were stained with mouse anti-FLAG primary
antibody and anti-mouse fluorescein isothiocyanate (FITC)-conjugated secondary antibody. LPHN3 surface expression was measured as green fluorescence
from FITC (x axis). FLRT3 LRR binding to FL-LPHN3-expressing cells was measured by monitoring red fluorescence of DyLight attached to neutravidin (y axis).
(Refer to Figure S3B and Table S3 for detailed experimental setup and experimental conditions.) Dot plot shows correlation between LPHN3 expression and
FLRT3 binding in LPHN3-transfected cells (blue), or in untransfected cells (black). Black ovals on the plot show the ‘‘high LPHN3 expression and high FLRT3
binding’’ gate. The number on the plot represents the percentage of all events that is in the high expression and high binding gate. 100 nM purifiedWT His-tagged
FLRT3 LRR domain was incubated with Biotin-Tris-NTA andwas tetramerized with neutravidin to increase avidity before binding to cells (see setup in Figure S3B).
Mutant FL-LPHN3 constructs (M21, M28) show proper surface expression (x axis), but do not bind FLRT3 LRR (y axis).
(B) Quantification of cells that fall within the gate of ‘‘high LPHN3 expression and high FLRT3 binding’’ (black ovals as indicated in A) normalized toWT. Bar height
represents the percentage of cells that falls within the gates shown.
See also Figures S3 and S4.To test whether this model is correct, we expressed full-
length UNC5D or full-length UNC5B in HEK293 cells and added
pre-mixed purified recombinant FLRT3 LRR, purified recombi-
nant biotinylated LPHN3 Olf, and neutravidin onto the cells
(see Figure 6B for a schematic representation of the experi-
ment). Bound LPHN3 Olf was detected using flow cytometry.
Our results showed that LPHN3 is detected on cells only
when FLRT3, LPHN3, and neutravidin are all added, indicating
the formation of a trimeric complex (Figures 6C and 6D; see
Figure S7 for raw data). No LPHN3 binding was detected
when FLRT3 was not added onto UNC5-expressing cells, sug-
gesting that there is no direct interaction between UNC5 and
LPHN3; instead, FLRT3 bridges the two proteins to form a
trimeric complex. As mentioned above, due to avidity, by tetra-
merizing biotinylated LPHN3 Olf with neutravidin, the effective
concentration of the FLRT3- LPHN3 affinity is more than 100-
fold higher than the concentration used. Similar results were
observed both with low or high protein concentrations with
UNC5D. Flow cytometry experiments performed with the puri-
fied FLRT3-UF LRR mutant showed that this mutant does not
completely abolish UNC5 binding, consistent with the previous
experiments (Figures 4A and 6E). These results suggest the for-
mation of a trimeric complex between UNC5, FLRT, and LPHN
in vitro.
LPHN3/FLRT3 and FLRT3/UNC5 Mediate Formation of
Intercellular Contacts
Cell-adhesion molecules may function in two different ways:
Two cell-adhesion molecules expressed on the same cell might
be involved in cis interactions or two cell-adhesion molecules
each expressed on one of the two neighboring cells might be
involved in trans interactions. To examine if trans interactions be-
tween LPHN3, FLRT3, or UNC5D can support cell-cell adhesion,Structure 23, 1678–16we performed cell-aggregation assays with non-adherent
HEK293 cells in which each full-length protein is expressed on
different cell populations and the cells are then mixed to monitor
cell aggregation (Figure 7). Previous studies have shown that
LPHN1 binding to Teneurin2 (Ten2) in trans can promote cell ag-
gregation (Boucard et al., 2014). Therefore, this condition was
used as a positive control in cell-aggregation experiments. Inter-
estingly, we found that the binding of FL-LPHN3 to FL-FLRT3
and of FL-UNC5D to FL-FLRT3 both induce cell-cell adhesion
in trans. Point mutations in both FL-LPHN3 and FL-FLRT3 in res-
idues that we found to be essential for complex formation in vitro
abolish cell aggregation (Figure 7). LPHN3, FLRT3, and UNC5D
form a heterotrimeric complex, wherein LPHN3 and UNC5D
bind to distinct binding sites on FLRT3. We observed no cell ag-
gregates mediated by homophilic interactions of any of these
molecules, in particular FL-FLRT3 or FL-Ten2, suggesting that
the hemophilic binding of these molecules operates in an exclu-
sively cis configuration (Figure 7D). Together, these results sup-
port the notion that LPHN3, FLRT3, and UNC5D function in
trans-cellular adhesion.
DISCUSSION
Neural development is a complex phenomenon that is medi-
ated by the coordinated interactions of numerous cell-surface
proteins on neurons and glial cells. Studying binary protein in-
teractions is a required but insufficient step in understanding
neural development, as other interaction partners of the binary
interaction in question likely affect the functional outcome of
the specific protein-protein interaction. This outcome also de-
pends on whether the cell-surface proteins are presented
from two different cells, making a trans interaction, or whether
they are presented on the same cell, making a cis interaction: in91, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1685
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Figure 4. Mutations on FLRT3 Abolish
LPHN3 Binding But Do Not Interfere with
Proper Cell-Surface Localization
(A) Wild-type (WT) and mutant full-length
FLRT3 proteins were tested for surface
expression in HEK293 cells as well as their
ability to bind soluble LPHN3 Olf domain using
flow cytometry. Non-permeabilized HEK293
cells expressing N-terminally Myc-tagged FL-
FLRT3 were stained with mouse anti-c-Myc
primary antibody and anti-mouse FITC-conju-
gated secondary antibody. FLRT3 surface
expression was measured as green fluores-
cence from FITC (x axis). Biotinylated LPHN3
Olf binding to FL-FLRT3-expressing cells was
measured by monitoring red fluorescence of
DyLight attached to neutravidin (y axis). (Refer
to Figure S3C and Table S3 for detailed
experimental setup and experimental condi-
tions.) Dot plot shows correlation between
FLRT3 expression and LPHN3 binding in
FLRT3-transfected cells (blue), or in un-
transfected cells (black). See legend of
Figure 3 for details; see also the setup in
Figure S3C. Mutant FLRT3 constructs (M2,
M6, FLRT-FF, and FLRT-UF) show proper
surface expression (x axis), but do not bind
LPHN3 (y axis) except FLRT3-UF. Different
sets of experiments are separated with
dashed black lines. WT data are provided for
each set of experiments as positive control.
(B) Quantification of cells that fall within the
gate of ‘‘high FLRT3 expression and high
LPHN3 binding’’ (black ovals as indicated in A)
normalized to WT. Bar height represents the percentage of cells that falls within the gates shown. See also Figure S3.
(C) Differential scanning fluorimetry of WT and mutant FLRT3 LRR and LPHN3 olfactomedin, domains showing the melting temperature (Tm).
See also Figure S5.many cases, cis and trans interactions are mutually exclusive in
that only one is possible when the respective proteins are
embedded in the plasma membrane. Studying the basics of
the specific protein-protein interactions and designing binding
mutants that specifically abolish one interaction without inter-
fering with the other interactions of a protein are essential first
steps before moving forward with functional understanding of
each protein.
In this study, using a combination of biophysical, biochemical,
and cell-based approaches, we studied the structure and spec-
ificity of the interaction between FLRT3 and LPHN3, and also
considered the interaction of FLRT3 with UNC5 and with itself.
The structure of the LPHN3/FLRT3 complex revealed that the
Olf domain was bound to the concave surface of the FLRT3
LRR horseshoe (Figure 1). The interaction surface spreads over
the extensive complementary surfaces of both proteins. Howev-
er, the major interaction hotspot is at the N-terminal top side of
the LRR horseshoe and at the long loops emerging from the sec-
ond and third blades of the LPHN3 Olf b propeller (Figure 2). The
concave surface of the FLRT3 LRR domain was previously re-
ported to mediate FLRT3 dimerization, so it is essential to study
the effect of any mutations in this region on both LPHN3 binding
and FLRT3 dimerization before commenting on the effect of the
mutation on the function of the protein. This surface is spatially
separated from the UNC5-binding site on FLRT3, and thus1686 Structure 23, 1678–1691, September 1, 2015 ª2015 Elsevier LtUNC5 binding and LPHN3 binding are likely not exclusive. On
the other hand, the FLRT3-binding site on LPHN3 is likely distant
from the teneurin-binding site on LPHN3, as teneurin binding is
largely mediated by the lectin domain and the splice insert,
both of which are at the N-terminal side of the Olf domain. Map-
ping of the mutations of LPHN3 genes that are linked to ADHD
and cancers on the LPHN3/FLRT3 complex structure reveals
that most mutations are at the LPHN3/FLRT3-binding interface
where the two proteins come closest to each other, and one mu-
tation is at the edge of the binding interface, suggesting protein-
protein interaction defects (Figures 2B and 2C).
Mapping the conserved and variable residues on the surface
of the LPHN3 and FLRT3 structures and relating their location
to the interface between FLRT3 and LPHN3 in the LPHN3/
FLRT3 structure shows that the FLRT3-binding site on LPHN3
and the LPHN3-binding site on FLRT3 are highly conserved.
This observation again suggests a critical role for LPHN/FLRT
interaction in neural development (Figure 1D). Mapping the elec-
trostatics surface potential on the LPHN3/FLRT structure shows
a large positive and a large negative surface at the concave in-
side surface of the LRR horseshoe, suggesting that non-specific
charge-charge interactions might be mediated via this surface,
especially at high protein concentrations (Figure 1E).
To confirm that the binding interface revealed by the LPHN/
FLRT complex structure is biologically relevant, we designedd All rights reserved
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Figure 5. Oligomerization ofWT andMutant
FLRT LRR Domains
(A–E) Size-exclusion gel filtration profile showing
elution volumes of WT FLRT3 LRR domain or
mutants at various protein concentrations. Protein
concentration is monitored by the UV absorbance
at 280 nm (mAu) indicated by the y axis. Different
colors of the y axis match the different elution
peaks. Blue, gray, and red curves indicate dimer,
intermediate, or monomer FLRT3 LRR, respec-
tively. Note that M2 mutant displays WT behavior.
Due to low protein yield, the protein could not be
concentrated to high enough concentrations to
form dimers. However, the observed intermediate
peak elutes at concentrations similar to those
of WT (note similar mAu in the y axis). See also
Figure S6.FLRT3 mutants and LPHN3 mutants that specifically disrupt
the LPHN/FLRT interaction without interfering with membrane
localization (Table 2; Figures 3 and 4). Flow cytometry binding
experiments showed that mutations located on the interaction
surface break the interaction. Flow cytometry experiments
monitoring cell-surface expression of the mutants on non-per-
meabilized cells showed that some mutations affect the proper
folding/trafficking of the proteins (Figures S3 and S4). Thus,
only well-expressed and trafficked mutants were used in further
experiments. All selected FLRT3 mutants were tested for their
ability to dimerize, to ensure only one specific interaction is
broken in any given mutant (Figure 5). Thus, we generated
well-characterized FLRT3 mutants and LPHN3 mutants that
can be used as molecular tools in further experiments to
specifically dissect the mechanism of these multi-interaction
proteins.
Importantly, we studied the previously reported ‘‘FLRT3
dimerization mutant-FF’’ (Seiradake et al., 2014) and showed
that the LPHN3-binding ability of this mutant is more severely
affected than its dimerization ability (Figures 4A and 5B). Consid-
ering that previously performed in vivo studies reported the
FLRT-FF mutant impairs tangential (sideways) migration of neu-
rons during cortex development, we suggest that the lack of
LPHN3 binding to the FLRT3-FF mutant might be responsible
for this defect. The high conservation of the binding interfaces
and the localization of ADHD and cancer mutations at the
LPHN/FLRT-binding surface also suggest a critical role for this
interaction. Similar considerations might apply to the mutantsStructure 23, 1678–1691, September 1, 2015 ªstudied in another recent paper (Jackson
et al., 2015), as all these mutations
include introduction of a new N-linked
glycosylation site into the protein
sequence.
The availability of the LPHN3/FLRT3
complex structure allowed us to make
comparisons with the FLRT2/UNC5D
complex structure and predict that
LPHN3 and UNC5D can simultaneously
interact with FLRT (Figure 6A). Our bind-
ing experiments showed that FLRT,
LPHN, and UNC5 form a trimeric com-
plex, and FLRT binds the other two proteins simultaneously
and bridges themwhere LPHN andUNC5 do not directly interact
with each other (Figure 6). Our cell-adhesion assays showed that
LPHN3/FLRT3 binding induces trans-cellular adhesion. Muta-
tions in the binding interface of LPHN3 and FLRT3 abrogated
cell adhesion. Interestingly, while FLRT3/UNC5D binding also in-
duces cell aggregation, LPHN3/UNC5D binding does not.
Together, these results suggest that LPHN3 and UNC5D are
localized to one side of the cellular junction in which they partic-
ipate, whereas FLRT3 is localized to the other side (Figure 7D). At
least LPHN3 and FLRT3 have been localized to synapses in
mature brain, suggesting that the LPHN3/FLRT3 and the
FLRT3/UNC5D interaction may, among others, contribute to
synapse formation and/or synaptic transmission. However, the
precise pre- versus postsynaptic localization of these proteins,
as well as whether they are necessary and/or sufficient for syn-
aptic adhesion, remains to be elucidated: for none of these pro-
teins has it actually been shown directly whether they are pre- or
postsynaptic. While FLRT3 appears to form a homodimer, we
were unable to observe FLRT3-FLRT3 cell aggregation. Thus,
this homodimer likely occurs in cis and is incapable of supporting
trans-cellular adhesion. Interestingly, the concurrent trans-
cellular interaction of FLRT3 with both UNC5D and LPHN3,
and the likely simultaneous trans-cellular interaction of LPHN3
in turn with both FLRT3 and teneurins, creates an interaction
network in which the cells are linked at an intercellular junction
such as the synapse, not by a simple one-to-one complex but
by a large complex composed of very different simultaneous2015 Elsevier Ltd All rights reserved 1687
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Figure 6. Formation of a Trimeric Complex between FLRT3, LPHN3, and UNC5 Proteins
(A) Superimposition of LPHN3/FLRT3 and FLRT2/UNC5D (PDB: 4V2C) structures.
(B) Simple schematic diagram of the experimental design for the detection of the trimeric complex on HEK293 cells. Refer to Figure S3D and Table S3 for detailed
experimental setup and experimental conditions.
(C) Quantification of purified biotinylated LPHN3 Olf binding to HEK293 cells transfected with FL-UNC5D. FLRT3 LRR domain (non-biotinylated), biotinylated
LPHN3 Olf domain, and neutravidin (allowing tetramerization) were mixed at different combinations at concentrations of 5 or 100 nM (Figure S7D), and red
fluorescence of DyLight attached to neutravidin was detected by flow cytometry. Pre-tetramerization of FLRT3 and LPHN3 with neutravidin increases avidity (for
raw data see Figure S7A).
(D) Same experiment as in (C) performed using UNC5B instead of UNC5D, using 100 nM pre-tetramerized complex (for raw data see Figure S7B).
(E) Same experiment as in (D) using FLRT3-UF mutant (for raw data see Figure S7C).
See also Figure S7.interactions that may be independently regulated, and may
transduce distinct trans-cellular signals.
In conclusion, the available high-resolution structure of the
LPHN3/FLRT3 complex provides the basis for further advances
in understanding their mechanism of action in brain function,
which may lead to the treatment of diseases caused by muta-
tions in these proteins.
EXPERIMENTAL PROCEDURES
See Supplemental Methods.
Vectors and Cloning
For crystallization and protein purification, the LRR repeats of human FLRT3
(residues K29–D357; UniProt: Q9NZU0) and the Olf domain of human
LPHN3 (residues V132–G392; UniProt: Q9HAR2) were cloned into pAcGP67a.
Similarly, the immunoglobulin-like domain of mouse Unc5D (residues G49–
Q161; UniProt: Q6UXZ4) was cloned into pAcGP67a. An 8xHis tag or biotin
tag was added at the C terminus for affinity purification. For mammalian
expression and functional analysis, full-length human FLRT3 (residues S30–
S649), human LPHN3 (residues F20–L1,447), and human Unc5B (G27–E934;
UniProt: Q8IZJ1), andmouse Unc5D (S46–L884) constructs with preprotrypsin1688 Structure 23, 1678–1691, September 1, 2015 ª2015 Elsevier Ltleader sequence containing N-terminal myc, FLAG, His, and His-tags, respec-
tively, were cloned into pCMV5.
Protein Expression, Purification, Crystallization, and Structure
Determination
A baculovirus expression system was used for expression of proteins used for
crystallization and biophysical experiments. The secreted, glycosylated pro-
teins were purified using nickel-nitrilotriacetic agarose resin (Qiagen) and
size-exclusion chromatography (Superdex 200 10/300 GL; GE Healthcare).
Prior to crystallization, purified proteins were incubated with carboxypepti-
dase A and carboxypeptidase B to cleave off the C-terminal residues such
as the His8 tag. Crystals of FLRT3 grew in 0.1 M Tris (pH 7) and 50% (v/v)
PEG200. Crystals of LPHN3/FLRT3 complex grew in 10% (w/v) PEG3000,
100 mM 2-(N-morpholino)ethanesulfonic acid (pH 6.0), and 200 mM lithium
sulfate.
Diffraction data were collected at Advanced Photon Source of the Argonne
National Laboratories beamline 23-IBD and 19-BM. Datasets were processed
using HKL2000. FLRT3 structure was solved by molecular replacement with
Phaser-MR (PHENIX) using a model of FLRT structure (PDB: 4V2E). Similarly,
LPHN3/FLRT3 structure was determined by molecular replacement using a
homology model of the LPHN3 Olf domain based on the myocilin Olf domain
crystal structure (PDB: 4WXQ). For both structures, refinement was performed
in phenix.refine (PHENIX) with non-crystallographic symmetry restraints.d All rights reserved
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Figure 7. Analysis of LPHN3/FLRT3/UNC5D Trans Interactions
(A) Representative images from cell-aggregation assays with WT full-length proteins. LPHN3 induces cell aggregation with FLRT3, as well as Ten2, a previously
identified trans interaction partner (Boucard et al., 2014). FLRT3 promotes trans-cellular adhesion with LPHN3 and UNC5D, but not with Ten2.
(B) Quantification of cell-aggregation assays with WT proteins (means ± SD). ***p < 0.001.
(C) Point mutations that disrupt LPHN3-FLRT3 binding abolish cell aggregation. Cell adhesion is preserved between LPHN3 and FLRT3when the UNC5D-binding
site on FLRT3 is mutated. All experiments were performed in three independent culture preparations. ***p < 0.001.
(D) Diagram of LPHN3/FLRT3/UNC5D/Ten2 at a cellular junction. LPHN3 and UNC5D are localized to the opposing membrane, which contains FLRT3 and Ten2.
Note: proteins are not drawn to scale. Adhesion will cause aggregates of two or more cells and, therefore, an increase in aggregation index. Aggregation index
was calculated using the program ImageJ.
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Simulated annealing was performed for the FLRT3 only structure. Olf structure
in the complex was further refined using LPHN3 Olf structure (PDB: 5AFB).
Since LPHN3/FLRT3 complex crystal displayed twinning, the twin law of h,
-k, -l was employed throughout the refinement process.
Flow Cytometry
Full-length proteins were expressed in the HEK293 mammalian expression
system. To test LPHN3 WT and mutant expression, transfected cells were
stained with mouse anti-FLAG M2 antibodies, 1:1,000 (F3165, Sigma). Fluo-
rescence was determined by incubating with anti-mouse fluorescein isothio-
cyanate (FITC). To test FLRT3 WT and mutant expression, cells were stained
with mouse anti c-Myc antibodies (9 3 1010; DSHB), 1:20 and anti-mouse
FITC, 1:100. For binding assays, purified monomeric or tetrameric soluble
proteins were added to primary antibodies. Pre-complex of BTtrisNTA-Neu-
trAvidinDyLight 650 (NAV650) (84607; Thermo Scientific) or only NeutrAvidin-
DyLight 650 (NAV650) was used for fluorescent labeling.
Cell-Aggregation Assays
FreeStyle HEK293 cells (Life Technologies) grown to a density of 1 3 106
cells/ml in a 30-ml volume were co-transfected with 30 mg of either pCMV-
Emerald or pCMV-dsRed and 30 mg of the indicated construct using Free-
Style Max reagent (Life Technologies). Live cells were imaged by dropping
100 ml of cell suspension onto a glass slide (FisherBrand). Aggregation index
was calculated as shown previously (Boucard et al., 2014).
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